Related Experiment Videos
[Immunologic therapy for glomerulonephritis with combined immunoadsorption and IVIG therapy]
14. Medizinische Abteilung-Klinische Immunologie/Rheumatologie, Krankenhaus Bogenhausen, Lehrkrankenhaus der TU München.
Immunitat Und Infektion
|August 1, 1995
Summary
Immunoadsorption combined with IVIG therapy shows promise for Systemic Lupus Erythematosus (SLE) patients with moderate kidney involvement. However, it offered limited benefits for patients with end-stage kidney disease or Wegener's vasculitis.
Area of Science:
- Nephrology
- Immunology
- Extracorporeal Therapy
Context:
- Immunoadsorption is an advanced extracorporeal therapy.
- Over 270 immunoadsorption procedures have been performed globally.
- This study investigates its efficacy in combination with IVIG.
Purpose:
- To evaluate the effectiveness of combined immunoadsorption and IVIG therapy.
- To assess treatment outcomes in patients with SLE and Wegener's vasculitis.
- To determine the impact on kidney involvement in these autoimmune diseases.
Summary:
- Seven patients with SLE and glomerulonephritis and three with Wegener's vasculitis received immunoadsorption and IVIG therapy.
- Patients with SLE and moderate kidney involvement showed improvement.
- Limited benefits were observed in SLE patients with end-stage kidney disease and Wegener's vasculitis patients, except for one case of reduced proteinuria.
Impact:
- Combined immunoadsorption and IVIG therapy may benefit select SLE patients with moderate renal disease.
- This approach shows limited efficacy for advanced kidney disease in SLE and Wegener's vasculitis.
- Further research is needed to refine treatment strategies for autoimmune-related glomerulonephritis.